The Global kifunensine market is expected to grow at a significant CAGR during the forecast period. Kifunensine is a mannosidase I inhibitor that is largely utilised in cell culture to produce high mannose glycoproteins. It stops the endoplasmic reticulum mannosidase I (ERM1) enzyme from trimming mannose residues from precursor glycoproteins inside the cell. Sarcoglycanopathies and lysosomal storage diseases have been treated by kifunensine. The European Commission approved the kifunensine orphan designation for the treatment of beta sarcoglycanopathy. The therapeutic potential of kifunensine is now being investigated in several diseases that benefit from its ability to inhibit mannosidase I.

Kifunensine inhibited the formation of complex types of oligosaccharides by human skin fibroblasts or aortic endothelial cells at concentrations of 1 ug/ml or higher in the culture medium, resulting in the accumulation of (GlcNAc) oligosaccharides on cell surface N-linked glycoproteins, and more specifically on the scavenger-LDL receptor. Endoplasmic reticulum-associated degradation (ERAD) inhibits the natural folding of mutant lysosomal enzymes in a patient's fibroblasts in lysosomal storage diseases such as Gaucher's disease and Tay Sachs illness.

Owing to its inhibitory effect, kifunensine is used in the growth of transformed mammalian cells to produce high mannose glycoproteins. It is faster to alter the glycosylation of a glycoprotein by combining a culture medium component with an already transformed cell line than it is to create a new cell line especially if a large number of cell lines or leads are being tested. Increasing the use of kifunensine for the cell culture produce glycoprotein and other diseases will drive the kifunensine market globally.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment covered 

o By Type

o By Application

• Region covered

o North America

o Europe

o Asia-pacific

o Rest of world

• Competitive Landscape- Glentham Life Sciences, R&D Systems, STEMCELL Technologies, Tocris Bioscience, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Kifunensine Market Segmentation

• By Type

o Low Purity (Below 97%)

o Purity (Above 97% and Below 99%)

o High Purity (Above 99%)

o Others

• By Application

o Cancer Treatment

o Neurological Treatment

o Endocrinological Treatment

o Others

Global Kifunensine Market by Region